



Network Oncology, Inc. enters into agreement with one of five major public hospital buying groups to supply two of its cancer products - Paclitaxel Resolute and Oxaliplatin Resolute in Germany

Vancouver, B.C., February 11, 2015 – Network Oncology Inc. (“Network Oncology”, “the Company”) has signed a supply agreement with a consortium of up to 70 public hospitals distributed throughout Germany to supply two of its oncology generic products. Network Oncology possesses a well-diversified portfolio of drug assets and plans to use its technical and commercial expertise to develop, launch, market and sell their portfolio of value-added products and services throughout Europe while offering significant cost savings to patients and payers.

Commenting on the agreement, Sean Maenpaa, CEO stated, “This is a significant development for the Company’s commercialization efforts in Germany as it further endorses the excellent products and services that Network Oncology is currently and will continue to deliver to its customers.”

The Company is expected to launch several more oncology products in the next twelve months to broaden its portfolio and services to healthcare professionals.

About Network Oncology Inc.

Network has acquired and is currently selling a core portfolio of oncology generic products for the European markets with possible expansion to other territories. The Company is commercially focussed and is dedicated to serving the oncology marketplace by understanding local market dynamics and its customers unmet needs. In addition, the Company has the ability to identify and pursue profitable segments of the oncology market in conjunction with providing value-added products and support services for its portfolio. Network also possesses the knowledge and capability to develop and commercialize differentiated versions of existing cancer products where an unmet need currently exists.

Further Information

Further details are available under the Company’s profile on SEDAR at www.sedar.com, and the Company’s profile on the CSE’s website at www.cnsx.ca

Contact:

Sean Maenpaa, President, CEO, and Director

Telephone: +353(0)874601340

E-mail: info@networkoncology.com

Website: www.networkoncology.com

Canadian Securities Exchange: Symbol **NOI**

Deutsche Boerse Xetra - Frankfurt Stock Exchange: Symbol **2NY**; WKN#: A11827

Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Network. Forward-looking information is based on certain key expectations and assumptions made by the management of Network, including future plans for the distribution of oncology products. Although Network believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Network can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. Network disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.